Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from ...

BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived ...

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare ...

Grifols, S.A. (NASDAQ:GRFS) is a company that unfortunately has not been performing as I expected it to. My position is in the green, but this has more to do with FX and me adding shares below my ...

Grifols SA has entered into a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to ...

Grifols (GRFS) has established a partnership with the Biomedical Advanced Research and Development Authority to test investigational ocular ...

Episode three of The Leaders’ Room’s season two features Grifols Ireland lead, Shane O’Brien. This series is created in partnership with IDA Ireland.

A successful preclinical study of this potentially innovative therapeutic could lead to an FDA license for one of the first medical treatments for sulfur mustard ocular injury Grifols also plans to ...

El Economista Grupo Editorial, S.a. De C.v. Sept 30 (Reuters) - Spanish drugmaker Grifols (GRLS.MC), opens new tab plans to invest 360 million euros ($401.98 million) to build a new industrial ...

LONDON, Sept 30 (Reuters) - Canadian fund Brookfield (BN.TO), opens new tab reaffirmed its interest in a potential takeover of Spanish drugmaker Grifols (GRLS.MC), opens new tab and requested more ...

BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has ...

BARCELONA - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company, has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate ...